TAU targets drug-resistant ovarian tumors with nanotechnology
Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.
Now Prof. Dan Peer of Tel Aviv University‘s Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer’s Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU’s Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits.
The objective of Peer’s research is two-fold: to provide a specific target for anti-cancer drugs to increase their therapeutic benefits, and to reduce the toxic side effects of anti-cancer therapies. The study was published in February in the journal ACS Nano.
Why chemotherapy fails
According to Prof. Peer, traditional courses of chemotherapy are not an effective line of attack. Chemotherapy’s failing lies in the inability of the medicine to be absorbed and maintained within the tumor cell long enough to destroy it. In most cases, the chemotherapy drug is almost immediately ejected by the cancer cell, severely damaging the healthy organs that surround it, leaving the tumor cell intact.
But with their new therapy, Peer and his colleagues saw a 25-fold increase in tumor-accumulated medication and a dramatic dip in toxic accumulation in healthy organs. Tested on laboratory mice, the gagomer mechanism effects a change in drug-resistant tumor cells. Receptors on tumor cells recognize the sugar that encases the gagomer, allowing the binding gagomer to slowly release tiny particles of chemotherapy into the cancerous cell. As more and more drugs accumulate within the tumor cell, the cancer cells begin to die off within 24-48 hours.
“Tumors become resistant very quickly. Following the first, second, and third courses of chemotherapy, the tumors start pumping drugs out of the cells as a survival mechanism,” said Prof. Peer. “Most patients with tumor cells beyond the ovaries relapse and ultimately die due to the development of drug resistance. We wanted to create a safe drug-delivery system, which wouldn’t harm the body’s immune system or organs.”
The Latest on: Ovarian cancer
via Google News
The Latest on: Ovarian cancer
- Parliament Hill crowd attends male-driven benefit in support of ovarian cancer researchon January 24, 2020 at 12:37 pm
From left, Bobby Sutherland, executive director of government affairs at Innovative Medicines Canada, George Wamala, director of regulatory and government affairs for RBC and Greg MacEachern, senior ...
- Mereo BioPharma, Oncologie Form License Agreement for Ovarian Cancer Treatmenton January 24, 2020 at 3:40 am
Navicixizumab is an anti-DLL4/vascular endothelial growth factor (VEGF) bispecific antibody that is currently being evaluated, in combination with paclitaxel, for the treatment of patients with ...
- Ovarian Cancer Drugs Market 2020 Size, Statistics, Growth, Revenue, Analysis & Trends Industry Forecast Report -2025|Market Research Engineon January 23, 2020 at 3:50 am
New York, January 23, 2020: The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled ...
- Myriad Submits sPMA for myChoice® CDx with Zejula® in First-Line Platinum Responsive Advanced Ovarian Canceron January 22, 2020 at 4:28 pm
Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that it has submitted a supplementary premarket approval (sPMA) application to the U.S. Food and Drug ...
- Activation of Apelin Signaling Decreases VEGF Inhibitor Efficacy in Ovarian Cancer Treatmenton January 21, 2020 at 2:25 pm
The activation of apelin/APJ signaling significantly decreased the efficacy of VEGF inhibitors in endothelial cells, while disease-free survival (DFS) rates of patients with ovarian cancer treated ...
- Use of intrauterine devices may decrease risk for ovarian canceron January 21, 2020 at 5:24 am
About 14,000 women each year die of ovarian cancer, making it one of the deadliest gynecologic cancers. Moreover, 80% of ovarian cancer diagnoses occur only after the disease has progressed to a late ...
- New Data On Talcum Powder/Ovarian Cancer Connectionon January 16, 2020 at 9:00 am
The issue of talc-based powder putting women at increased risk for ovarian cancer was also a focus of many of the suits, although direct evidence of talcum powder acting as a potential cause of ...
- Ovarian Cancer Drugs Market 2020 Global Trends, Statistics, Size, Share, Regional Analysis By 2025-MRE Reporton January 14, 2020 at 3:52 am
New York, January 14, 2020: The global ovarian cancer drugs market is segmented on the lines of its technology, treatment, application and regional. Based on product type segmentation it covers oral ...
- Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitmenton January 13, 2020 at 3:10 pm
The mechanism of resistance development to anti-VEGF therapy in ovarian cancer is unclear. We focused on the changes in tumour immunity post anti-VEGF therapy. The frequencies of immune cell ...
- Protein associated with ovarian cancer exacerbates neurodegeneration in Alzheimer'son January 13, 2020 at 7:12 am
Houston Methodist scientists identified a protein found in ovarian cancer that may contribute to declining brain function and Alzheimer's disease, by combining computational methods and lab research.
via Bing News